UY31454A1 - Uso de un gestageno en combinacion con un estrogeno y uno o varios excipientes/portadores farmacéuticamente aceptables para la anticoncepcion oral sin lactosa - Google Patents

Uso de un gestageno en combinacion con un estrogeno y uno o varios excipientes/portadores farmacéuticamente aceptables para la anticoncepcion oral sin lactosa

Info

Publication number
UY31454A1
UY31454A1 UY31454A UY31454A UY31454A1 UY 31454 A1 UY31454 A1 UY 31454A1 UY 31454 A UY31454 A UY 31454A UY 31454 A UY31454 A UY 31454A UY 31454 A1 UY31454 A1 UY 31454A1
Authority
UY
Uruguay
Prior art keywords
lactose
pharmaceutically acceptable
combination
oract
strogen
Prior art date
Application number
UY31454A
Other languages
English (en)
Inventor
Beate Burglen
Manuela Pfeifer
Sabine Fricke
Claus Claussen
Ralf Ladwig
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of UY31454A1 publication Critical patent/UY31454A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)

Abstract

Los gesatágenos, con preferencia dienogest, acetato de clormadinona o levornogetrel en combinacion con estrogenos tales como, por ejemplo, etinilestradiol, 17B(Beta)-estradiol o valerato de estradiol y uno o varios excipientes/portadores faramcéuticamente aceptables realizan un anticoncepcion oral sin lactosa. Se da una posibilidad para mejorar la prevencion de la intolerancia a la glucosa en un factor que eventualmente contribuye con la mejoría, incluso en cuanto a costosos ensayos de la intolerancia a la glucosa. La invencion también es apropiada para un uso prolongado.
UY31454A 2007-11-05 2008-11-04 Uso de un gestageno en combinacion con un estrogeno y uno o varios excipientes/portadores farmacéuticamente aceptables para la anticoncepcion oral sin lactosa UY31454A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07021465A EP2055306A1 (de) 2007-11-05 2007-11-05 Verwendung eines Gestagens in Kombination mit einem Estrogen und einem oder mehreren pharmazeutisch annehmbaren hilfsstoffen/Trägern zur laktosefreien oralen Kontrazeption

Publications (1)

Publication Number Publication Date
UY31454A1 true UY31454A1 (es) 2009-05-29

Family

ID=39016019

Family Applications (1)

Application Number Title Priority Date Filing Date
UY31454A UY31454A1 (es) 2007-11-05 2008-11-04 Uso de un gestageno en combinacion con un estrogeno y uno o varios excipientes/portadores farmacéuticamente aceptables para la anticoncepcion oral sin lactosa

Country Status (31)

Country Link
EP (3) EP2055306A1 (es)
JP (1) JP2011502136A (es)
KR (1) KR20100103794A (es)
CN (1) CN101848716B (es)
AR (1) AR069195A1 (es)
AT (1) AT12800U1 (es)
AU (1) AU2008324549A1 (es)
BR (1) BRPI0819189A2 (es)
CA (1) CA2704523A1 (es)
CO (1) CO6270329A2 (es)
CR (1) CR11413A (es)
DE (1) DE202007019049U1 (es)
DK (1) DK2217243T3 (es)
DO (1) DOP2010000130A (es)
EA (1) EA201000749A1 (es)
EC (1) ECSP10010152A (es)
ES (1) ES2511841T3 (es)
HK (1) HK1145289A1 (es)
HR (1) HRP20140962T1 (es)
IL (1) IL205349A0 (es)
MX (1) MX2010004975A (es)
NZ (1) NZ585065A (es)
PA (1) PA8803001A1 (es)
PE (1) PE20091020A1 (es)
PL (1) PL2217243T3 (es)
PT (1) PT2217243E (es)
SG (1) SG188118A1 (es)
TW (1) TW200936142A (es)
UY (1) UY31454A1 (es)
WO (1) WO2009059690A1 (es)
ZA (1) ZA201004024B (es)

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0368373A1 (en) * 1988-10-13 1990-05-16 Akzo Nobel N.V. Multi-phase contraceptive preparation
US5223268A (en) * 1991-05-16 1993-06-29 Sterling Drug, Inc. Low solubility drug-coated bead compositions
DK95093D0 (da) * 1993-08-20 1993-08-20 Novo Nordisk As Farmaceutisk formulering indeholdende et hormon
US5898032A (en) * 1997-06-23 1999-04-27 Medical College Of Hampton Roads Ultra low dose oral contraceptives with less menstrual bleeding and sustained efficacy
JPH1171268A (ja) * 1997-08-28 1999-03-16 Kayaku:Kk 性ホルモン含有錠剤
CA2260673A1 (en) 1999-02-04 2000-08-04 Natrel Inc. A process for making a lactose-free milk without negatively affecting the organoleptic properties thereof; and milk so processed
DE10043846A1 (de) * 2000-09-04 2002-04-04 Jenapharm Gmbh 17-Methylensteroide, Verfahren zu deren Herstellung und diese Verbindung enthaltende pharmazeutische Zusammensetzungen
FR2832065B1 (fr) * 2001-11-13 2004-11-05 Besins Int Belgique Composition pharmaceutique a base de progesterone micronisee son procede de preparation et ses utilisations
AU2004275470B2 (en) 2003-09-29 2010-12-02 Novo Nordisk Health Care Ag Improved stability of progestogen formulations
WO2005030175A1 (en) 2003-09-29 2005-04-07 Novo Nordisk Femcare Ag Hrt formulations
CN1672685A (zh) * 2004-03-26 2005-09-28 董可娟 一种新的避孕药物
DE102004019406A1 (de) * 2004-04-19 2005-11-03 Schering Ag 17α-Fluorsteroide
DE102004026671A1 (de) * 2004-05-28 2005-12-15 Grünenthal GmbH Darreichungsform zur hormonalen Kontrazeption
DE102004026670A1 (de) * 2004-05-28 2005-12-15 Grünenthal GmbH Hormonales Kontrazeptivum enthaltend eine Kombination aus Ethinylestradiol und Chlormadinonacetat
EP1690543A1 (de) * 2005-02-15 2006-08-16 Schering AG Pharmazeutisches Präparat zur Kontrazeption
EP1774970A1 (de) * 2005-10-13 2007-04-18 Bayer Schering Pharma AG Verfahren zur Herstellung eines einphasigen pharmazeutischen Präparates zur Therapie der dysfunktionellen uterinen Blutung, enthaltend Ethinylestradiol und Dienogest

Also Published As

Publication number Publication date
DK2217243T3 (da) 2014-10-20
CN101848716B (zh) 2012-11-28
CN101848716A (zh) 2010-09-29
EA201000749A1 (ru) 2010-12-30
BRPI0819189A2 (pt) 2015-05-26
AT12800U1 (de) 2012-11-15
CR11413A (es) 2010-06-17
PE20091020A1 (es) 2009-08-15
EP2217243B1 (de) 2014-08-06
HRP20140962T1 (hr) 2014-12-05
CO6270329A2 (es) 2011-04-20
PL2217243T3 (pl) 2014-12-31
AR069195A1 (es) 2010-01-06
ECSP10010152A (es) 2010-06-29
DE202007019049U8 (de) 2010-09-30
ZA201004024B (en) 2012-11-28
WO2009059690A1 (de) 2009-05-14
SG188118A1 (en) 2013-03-28
IL205349A0 (en) 2010-12-30
DE202007019049U1 (de) 2010-05-12
HK1145289A1 (en) 2011-04-15
DOP2010000130A (es) 2010-07-31
PA8803001A1 (es) 2009-06-23
ES2511841T3 (es) 2014-10-23
EP2217243A1 (de) 2010-08-18
KR20100103794A (ko) 2010-09-28
EP2774614A1 (de) 2014-09-10
NZ585065A (en) 2012-06-29
MX2010004975A (es) 2010-05-24
CA2704523A1 (en) 2009-05-14
AU2008324549A1 (en) 2009-05-14
PT2217243E (pt) 2014-09-24
TW200936142A (en) 2009-09-01
EP2055306A1 (de) 2009-05-06
JP2011502136A (ja) 2011-01-20

Similar Documents

Publication Publication Date Title
PE20061415A1 (es) Composicion farmaceutica que contiene gestagenos y/o estrogenos y 5-metil-(6s)-tetrahidrofolato
PE20080273A1 (es) Composicion farmaceutica que contiene un progestageno, un estrogeno y un acido tetrahidrofolico
PE20120860A1 (es) Combinacion farmaceutica que comprende levonorgestrel en combinacion con piroxicam, indometacina o diclofenaco
AR057060A1 (es) Composiciones de tanaproget que contienen etinil estradiol
CL2011003172A1 (es) Composicion farmaceutica que comprende a) un excepiente, b) al menos un precursor de esteroides sexuales, c) al menos un modulador selectivo del receptor de estrogenos o una antiestrogeno y no contiene una progestina y/o un estrogeno; kit farmaceutico; y uso para reducir o eliminar sofocos, sintomas vasomotores y sudores nocturnos.
PE20070208A1 (es) Anticoncepcion oral con trimegestona
PE20060275A1 (es) Composicion farmaceutica que contiene progestina y estrogeno para el tratamiento de trastorno disforico premenstrual
BRPI0512993A (pt) uso de um antagonista de pr, kit farmaceuticamente últil, e, método de contracepção em uma fêmea em idade de parto
AR064077A1 (es) Composiciones bajo forma de unguento sin vaselina que comprende un derivado de vitamina d y eventualmente un anti-inflamatorio esteroide
AR082998A1 (es) Asociacion farmaceutica para tratar y/o prevenir mioma y/o endometriosis, uso de resveratrol y progestogeno, composicion farmaceutica para tratamiento y/o prevencion de mioma y/o endometriosis, medicamento para tratamiento y/o prevencion de mioma y/o endometriosis, kit y metodo para tratamiento y/o prevencion de mioma y/o endometriosis
HN2008000621A (es) Metodo para la anticopcepcion hormonal preventiva bajo demanda
CR10259A (es) Metodos para la prevencion y tratamiento de condiciones que surgen de deficiencia de estrogeno local
ATE493132T1 (de) Arzneimittel umfassend wenigstens ein gestagen
UY39175A (es) Composiciones anticonceptivas con efectos adversos reducidos
AR049196A1 (es) Anticonceptivo hormonal conteniendo una combinacion de etinilestradiol y acetato de clormadinona
UY31454A1 (es) Uso de un gestageno en combinacion con un estrogeno y uno o varios excipientes/portadores farmacéuticamente aceptables para la anticoncepcion oral sin lactosa
CU20100084A7 (es) Uso de un gestágeno en combinación con un estrógeno y uno o varios excipientes/portadores farmacéuticamente aceptables para la anticoncepción oral sin lactosa
DOP2006000037A (es) Forma farmacológica peroral sólida para la anticoncepción
CL2008000999A1 (es) Composicion farmaceutica que comprende drospirenona y 17beta estradiol; kit farmaceutico que comprende a dicha composicion, util para terapia hormonal y contracepcion en mujeres.
PL1978970T3 (pl) Środek antykoncepcyjny
CR11211A (es) Estratienos 8-beta-sustituidos como estrogenos de accion selectiva
DE602004018921D1 (de) D dienogest
EA200900829A1 (ru) Фармацевтический препарат для уменьшения эндометриоза
GEP20135792B (en) Pharmaceutical compositions based on kinin b2 receptor antagonists and corticosteroids, and use of the same
WO2009140225A3 (en) Anti-inflammatory and immunosuppresive glucocorticoid steroids

Legal Events

Date Code Title Description
DESI Application deemed to be withdrawn

Effective date: 20091229